Showing results (51-60 of 244) with videos related to
Sort By:
Pageof 25
The Cancer Journal From Scientific American|June 15, 1999
One-hour paclitaxel infusions: review of safety and efficacyF A Greco, M Thomas, J D HainsworthArchives of Pathology & Laboratory Medicine|August 3, 2000
Abnormal erythrocyte anion exchange in Alzheimer diseaseF A Greco, A Satlin, A K SolomonJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary siteJ D Hainsworth, W J Lennington, F A GrecoSeminars in Oncology|February 1, 1990
Chronic daily administration of oral etoposideF A Greco, D H Johnson, J D HainsworthSeminars in Oncology|August 7, 1999
Weekly administration of docetaxel (Taxotere): summary of clinical dataJ D Hainsworth, H A Burris, F A GrecoAmerican Journal of Clinical Oncology|April 1, 1988
Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary siteJ D Hainsworth, T W Dial, F A GrecoCancer Treatment Reports|November 1, 1979
Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal MalignanciesP A DeSimone, F A Greco, H F LessnerAnnals of Internal Medicine|September 1, 1988
Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entityJ D Hainsworth, D H Johnson, F A GrecoAnnals of Internal Medicine|April 1, 1986
Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndromeF A Greco, W K Vaughn, J D HainsworthCancer Treatment Reviews|March 1, 1991
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancerF A Greco, D H Johnson, J D HainsworthPageof 25